Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

These ETFs Should Love The Pfizer-Allergan News

{{labelSign}}  Favorites
{{errorMessage}}

In what could amount to the biggest takeover of a U.S. company in over a year, Dow component Pfizer Inc. (NYSE: PFE) is reportedly mulling an acquisition of specialty pharmaceuticals maker Allergan Plc (NYSE: AGN).

"Pfizer recently approached Allergan about a deal, according to people familiar with the matter, with one of them adding that the process is early and may not yield an agreement. Other details of the talks are unclear," reports The Wall Street Journal.

Allergan closed with a market value of about $113 billion on Wednesday. Pfizer's market value at Wednesday's close was nearly double that. New York-based Pfizer had nearly $30.3 billion in cash on hand at the end of the second quarter.

As is par for the course with healthcare sector deal-making, a batch of exchange traded funds stand to benefit, particularly if ...

/www.benzinga.com/trading-ideas/long-ideas/15/10/5949034/these-etfs-should-love-the-pfizer-allergan-news alt=These ETFs Should Love The Pfizer-Allergan News>Full story available on Benzinga.com

Click to enlargeMore...


{{labelSign}}  Favorites
{{errorMessage}}